Khan, H.Y.; Ge, J.; Nagasaka, M.; Aboukameel, A.; Mpilla, G.; Muqbil, I.; Szlaczky, M.; Chaker, M.; Baloglu, E.; Landesman, Y.;
et al. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. Int. J. Mol. Sci. 2020, 21, 237.
https://doi.org/10.3390/ijms21010237
AMA Style
Khan HY, Ge J, Nagasaka M, Aboukameel A, Mpilla G, Muqbil I, Szlaczky M, Chaker M, Baloglu E, Landesman Y,
et al. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. International Journal of Molecular Sciences. 2020; 21(1):237.
https://doi.org/10.3390/ijms21010237
Chicago/Turabian Style
Khan, Husain Yar, James Ge, Misako Nagasaka, Amro Aboukameel, Gabriel Mpilla, Irfana Muqbil, Mark Szlaczky, Mahmoud Chaker, Erkan Baloglu, Yosef Landesman,
and et al. 2020. "Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance" International Journal of Molecular Sciences 21, no. 1: 237.
https://doi.org/10.3390/ijms21010237
APA Style
Khan, H. Y., Ge, J., Nagasaka, M., Aboukameel, A., Mpilla, G., Muqbil, I., Szlaczky, M., Chaker, M., Baloglu, E., Landesman, Y., Mohammad, R. M., Azmi, A. S., & Sukari, A.
(2020). Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. International Journal of Molecular Sciences, 21(1), 237.
https://doi.org/10.3390/ijms21010237